NF1-dependent disruption of the blood-nerve-barrier is improved by blockade of P2RY14.
biological sciences
molecular neuroscience
neuroscience
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
19 Jul 2024
19 Jul 2024
Historique:
received:
10
06
2022
revised:
17
12
2023
accepted:
14
06
2024
medline:
5
8
2024
pubmed:
5
8
2024
entrez:
5
8
2024
Statut:
epublish
Résumé
The blood-nerve-barrier (BNB) that regulates peripheral nerve homeostasis is formed by endoneurial capillaries and perineurial cells surrounding the Schwann cell (SC)-rich endoneurium. Barrier dysfunction is common in human tumorigenesis, including in some nerve tumors. We identify barrier disruption in human
Identifiants
pubmed: 39100928
doi: 10.1016/j.isci.2024.110294
pii: S2589-0042(24)01519-0
pmc: PMC11294707
doi:
Types de publication
Journal Article
Langues
eng
Pagination
110294Informations de copyright
© 2024 The Authors.
Déclaration de conflit d'intérêts
Some research in the N.R. lab is funded by Revolution Meidicines and Boehringer Ingelheim, unrelated to this study. D.A.L. is the co-founder and co-owner of NeoClone Biotechnologies, Inc., Discovery Genomics, Inc. (recently acquired by Immusoft, Inc.), B-MoGen Biotechnologies, Inc. (recently acquired by Bio-Techne Corporation), and Luminary Therapeutics, Inc. D.A.L. holds equity in, serves as a Senior Scientific Advisor for and Board of Director member for Recombinetics, a genome editing company. The business of all these companies is unrelated to the contents of this manuscript. D.A.L. consults for Styx Therapeutics, Inc. and 10.13039/100004328Genentech, Inc., which is funding some of his research.